SG
KDNY

StepStone Group’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

StepStone Group’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-9,277
Closed -$182K – 34
2022
Q3 		$182K Buy
+9,277
New +$186K 0.03% 23

Other funds holding KDNY

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

StepStone Group's KDNY Position: Q4 2022 in Review

StepStone Group sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q4 2022, closing a stake of 9,277 shares — an estimated $182K sold.

StepStone Group first reported a position in KDNY in Q3 2022 and held it in 1 quarter. The position peaked at $182K in Q3 2022. 155 funds tracked by Wall St. Rank hold KDNY as of Q4 2022.

  • StepStone Group reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • StepStone Group sold 9,277 Chinook Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $182K.
  • StepStone Group first reported a position in Chinook Therapeutics, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • StepStone Group's Chinook Therapeutics, Inc. Common Stock position peaked at $182K in Q3 2022.
  • 155 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q4 2022.

Based on StepStone Group's 13F filing for Q4 2022, filed 10 Feb 2023.